Abstract
To the Editor: I read with interest the article by Mahoney et al1 suggesting the cost advantage of prasugrel over clopidogrel; however, I found 3 aspects of their article confusing. First, frequency of rehospitalizations (Table 1 in their article) does not include extra cancers observed in the prasugrel arm of the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON) trial. Considering the 27% increase in new cancers ( P =0.031), the 36.8% …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
